Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Advanced Drainage Systems Announces Fourth Quarter and Fiscal 2019 Results

Published

on

Reading Time: 13 minutes

HILLIARD, Ohio–(BUSINESS WIRE)–Advanced Drainage Systems, Inc. (NYSE: WMS) (“ADS” or the “Company”), a
leading global manufacturer of water management products and solutions
for non-residential, residential, infrastructure and agricultural
applications, today announced financial results for the fourth quarter
and fiscal year ended March 31, 2019.

Fourth Quarter Fiscal 2019 Results

  • Net sales increased 8.8% to $272.2 million
  • Net income increased 139.0% to $1.9 million
  • Adjusted EBITDA (Non-GAAP) increased 36.5% to $36.9 million

Fiscal 2019 Results

  • Net sales increased 4.1% to $1,384.7 million
  • Net income increased 25.8% to $81.5 million
  • Adjusted EBITDA (Non-GAAP) increased 10.3% to $232.0 million
  • Cash provided by operating activities increased 10.6% to $151.7
    million
  • Free cash flow (Non-GAAP) increased 13.5% to $108.3 million

Scott Barbour, President and Chief Executive Officer of ADS commented,
“We closed out another strong year by achieving fourth quarter top and
bottom-line results, driven by disciplined execution of our market share
model and conversion strategy. The strength in our fourth quarter
results reflect increased volume across our key geographies for both
Pipe and Allied products, favorable pricing and operational efficiency
in manufacturing and transportation.”

Barbour continued, “Our commitment to continuous improvement and
best-in-class water management solutions propelled us to outperform our
core domestic construction markets by approximately 400 basis points in
fiscal 2019 and grow our share in the storm water market. In addition,
we delivered margin expansion of 100 basis points for the year driven by
price attainment, Allied product growth as well as disciplined execution
and cost containment. Looking ahead to fiscal 2020, we will continue to
deliver on our three-year plan to increase shareholder value by
capitalizing on our leadership position and strength in our end markets
to drive growth, while achieving sustained profitability and maintaining
a strong balance sheet.”

Fourth Quarter Fiscal 2019 Results

Net sales increased 8.8% to $272.2 million, as compared to $250.1
million in the prior year. Domestic net sales increased 11.1% to $251.2
million as compared to $226.2 million in the prior year, driven by a
12.8% increase in construction market sales. International net sales
decreased 12.1% to $21.0 million as compared to $23.9 million in the
prior year, driven primarily by a decrease in Mexico sales.

Gross profit increased 23.7% to $59.5 million, as compared to $48.1
million the prior year quarter. As a percentage of net sales, gross
profit increased 270 basis points to 21.9%, compared to 19.2% in the
prior year. The margin expansion is primarily due to an increase in
volume, favorable pricing and successful cost containment efforts.

Adjusted EBITDA (Non-GAAP) increased 36.5% to $36.9 million, as compared
to $27.0 million in the prior year quarter. As a percentage of net
sales, Adjusted EBITDA increased 270 basis points to 13.5% as compared
to 10.8% in the prior year. The increase in Adjusted EBITDA margin was
largely attributed to the factors mentioned above.

Reconciliations of GAAP to Non-GAAP financial measures for Adjusted
EBITDA and Free Cash Flow have been provided in the financial statement
tables included in this press release. An explanation of these measures
is also included below under the heading “Non-GAAP Financial Measures.”

Fiscal 2019 Results

Net sales increased 4.1% to $1,384.7 million, as compared to $1,330.4
million in the prior year. Domestic net sales increased 4.2% to $1,224.1
million, as compared to $1,174.4 million in the prior year, primarily
driven by solid construction market demand, favorable pricing and strong
Allied product sales. International net sales increased 2.9% to $160.6
million, as compared to $155.9 million in the prior year, driven
primarily by growth in our Exports business.

Gross profit increased 8.1% to $327.0 million, as compared to $302.5
million the prior year. As a percentage of net sales, gross profit
increased 90 basis points to 23.6%, compared to 22.7% in the prior year.
The margin increase is primarily due to favorable pricing and successful
cost containment efforts, partially offset by higher inflationary costs
on resin, transportation and wages, among others.

Adjusted EBITDA (Non-GAAP) increased 10.3% to $232.0 million, as
compared to $210.2 million in the prior year. As a percentage of net
sales, Adjusted EBITDA increased 100 basis points to 16.8% as compared
to 15.8% in the prior year. The increase in Adjusted EBITDA margin was
largely attributed to the factors mentioned above.

Net cash from operating activities increased 10.6% to $151.7 million, as
compared to $137.1 million in the prior year. Free cash flow (Non-GAAP)
increased 13.5% to $108.3 million, as compared to $95.4 million in the
prior year. Net debt (total debt and capital lease obligations net of
cash) was $310.3 million as of March 31, 2019, a decrease of $51.8
million from March 31, 2018.

Fiscal 2020 Outlook

Based on current visibility, backlog of existing orders and business
trends, the Company has provided its net sales and Adjusted EBITDA
targets for fiscal 2020. Net sales are expected to be in the range of
$1.425 billion to $1.475 billion and Adjusted EBITDA is expected to be
in the range of $245 to $265 million. Capital expenditures are expected
to be in the range of $55 million to $65 million.

Webcast Information

The Company will host an investor conference call and webcast on
Thursday, May 23, 2019 at 10:00 a.m. Eastern Time. The live call can be
accessed by dialing 1-844-484-0244 (US toll-free) or 1-647-689-5142
(international) and asking to be connected to the Advanced Drainage
Systems, Inc. call. The live webcast will also be accessible via the
“Events Calendar” section of the Company’s Investor Relations website, www.investors.ads-pipe.com.
An archived version of the webcast will be available for one year
following the call.

About the Company

Advanced Drainage Systems is the leading manufacturer of high
performance thermoplastic corrugated pipe, providing a comprehensive
suite of water management products and superior drainage solutions for
use in the construction and infrastructure marketplace. Its innovative
products are used across a broad range of end markets and applications,
including non-residential, residential, agriculture and infrastructure
applications. The Company has established a leading position in many of
these end markets by leveraging its national sales and distribution
platform, overall product breadth and scale and manufacturing
excellence. Founded in 1966, the Company operates a global network of
approximately 55 manufacturing plants and over 30 distribution centers.
To learn more about ADS, please visit the Company’s website at www.ads-pipe.com.

Forward Looking Statements

Certain statements in this press release may be deemed to be
forward-looking statements. These statements are not historical facts
but rather are based on the Company’s current expectations, estimates
and projections regarding the Company’s business, operations and other
factors relating thereto. Words such as “may,” “will,” “could,” “would,”
“should,” “anticipate,” “predict,” “potential,” “continue,” “expects,”
“intends,” “plans,” “projects,” “believes,” “estimates,” “confident” and
similar expressions are used to identify these forward-looking
statements. Factors that could cause actual results to differ from those
reflected in forward-looking statements relating to our operations and
business include: fluctuations in the price and availability of resins
and other raw materials and our ability to pass any increased costs of
raw materials on to our customers in a timely manner; volatility in
general business and economic conditions in the markets in which we
operate, including, without limitation, factors relating to availability
of credit, interest rates, fluctuations in capital and business and
consumer confidence; cyclicality and seasonality of the non-residential
and residential construction markets and infrastructure spending; the
risks of increasing competition in our existing and future markets,
including competition from both manufacturers of high performance
thermoplastic corrugated pipe and manufacturers of products using
alternative materials; our ability to continue to convert current demand
for concrete, steel and PVC pipe products into demand for our high
performance thermoplastic corrugated pipe and Allied Products; the
effect of weather or seasonality; the loss of any of our significant
customers; the risks of doing business internationally; the risks of
conducting a portion of our operations through joint ventures; our
ability to expand into new geographic or product markets; our ability to
achieve the acquisition component of our growth strategy; the risk
associated with manufacturing processes; our ability to manage our
assets; the risks associated with our product warranties; our ability to
manage our supply purchasing and customer credit policies; the risks
associated with our self-insured programs; our ability to control labor
costs and to attract, train and retain highly-qualified employees and
key personnel; our ability to protect our intellectual property rights;
changes in laws and regulations, including environmental laws and
regulations; our ability to project product mix; the risks associated
with our current levels of indebtedness; fluctuations in our effective
tax rate, including from the recently enacted Tax Cuts and Jobs Act;
changes to our operating results, cash flows and financial condition
attributable to the recently enacted Tax Cuts and Jobs Act; our ability
to meet future capital requirements and fund our liquidity needs; the
risk that additional information may arise that would require the
Company to make additional adjustments or revisions or to restate the
financial statements and other financial data for certain prior periods
and any future periods, any delay in the filing of any filings with the
Securities and Exchange Commission (“SEC”); the review of potential
weaknesses or deficiencies in the Company’s disclosure controls and
procedures, and discovering weaknesses of which we are not currently
aware or which have not been detected and the other risks and
uncertainties described in the Company’s filings with the SEC. New risks
and uncertainties emerge from time to time and it is not possible for
the Company to predict all risks and uncertainties that could have an
impact on the forward-looking statements contained in this press
release. In light of the significant uncertainties inherent in the
forward-looking information included herein, the inclusion of such
information should not be regarded as a representation by the Company or
any other person that the Company’s expectations, objectives or plans
will be achieved in the timeframe anticipated or at all. Investors are
cautioned not to place undue reliance on the Company’s forward-looking
statements and the Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.

Financial Statements

 
ADVANCED DRAINAGE SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
 
  Three Months Ended   Fiscal Year Ended
March 31, March 31,
(Amounts in thousands, except per share data) 2019   2018 2019   2018
Net sales $ 272,218 $ 250,114 $ 1,384,733 $ 1,330,354
Cost of goods sold   212,714   201,999   1,057,766   1,027,873
Gross profit 59,504 48,115 326,967 302,481
Operating expenses:
Selling 24,179 22,416 96,335 92,764
General and administrative 24,610 24,041 89,692 98,392

Loss on disposal of assets and costs from exit and disposal
activities

2,075 4,535 3,647 15,003
Intangible amortization   1,935   1,997   7,880   8,068
Income from operations 6,705 (4,874 ) 129,413 88,254
Other expense:
Interest expense 4,590 2,642 18,618 15,262
Derivative loss (gains) and other expense (income), net   (729 )   506   (815 )   (3,950 )
Income before income taxes 2,844 (8,022 ) 111,610 76,942
Income tax expense (benefit) 1,081 (4,401 ) 30,049 11,411
Equity in net (income) loss of unconsolidated affiliates   (130 )   1,235   95   739
Net income 1,893 (4,856 ) 81,466 64,792
Less: net income attributable to noncontrolling interest   883   847   3,694   2,785
Net income attributable to ADS 1,010 (5,703 ) 77,772 62,007
Dividends to redeemable convertible preferred stockholders (497 ) (443 ) (2,047 ) (1,858 )
Dividends paid to unvested restricted stockholders   (13 )   (2 )   (69 )   (49 )

Net income available to common stockholders and participating
securities

500 (6,148 ) 75,656 60,100

Undistributed income allocated to participating securities

      (5,474 )   (4,514 )
Net income available to common stockholders $ 500 $ (6,148 ) $ 70,182 $ 55,586
 
Weighted average common shares outstanding:
Basic 57,325 56,302 57,025 55,696
Diluted 57,823 56,302 57,611 56,334
Net income per share:
Basic $ 0.01 $ (0.11 ) $ 1.23 $ 1.00
Diluted $ 0.01 $ (0.11 ) $ 1.22 $ 0.99
Cash dividends declared per share $ 0.08 $ 0.07 $ 0.32 $ 0.28
 
 
ADVANCED DRAINAGE SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
 
  As of
(Amounts in thousands) March 31, 2019   March 31, 2018
ASSETS
Current assets:
Cash $ 8,891 $ 17,587
Receivables, net 186,991 171,961
Inventories 264,540 263,792
Other current assets   6,091   5,113
Total current assets 466,513 458,453
Property, plant and equipment, net 398,891 399,381
Other assets:
Goodwill 102,638 103,017
Intangible assets, net 37,177 44,437
Other assets   36,940   37,954
Total assets $ 1,042,159 $ 1,043,242
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of debt obligations $ 25,932 $ 26,848
Current maturities of capital lease obligations 23,117 22,007
Accounts payable 93,577 105,521
Other accrued liabilities 61,901 60,560
Accrued income taxes   1,758   6,307
Total current liabilities 206,285 221,243
Long-term debt obligations, net 208,602 270,900
Long-term capital lease obligations 61,555 59,963
Deferred tax liabilities 45,963 32,304
Other liabilities   19,119   25,023
Total liabilities 541,524 609,433
Mezzanine equity:
Redeemable convertible preferred stock 282,638 291,247
Deferred compensation — unearned ESOP shares (180,316 ) (190,168 )
Redeemable noncontrolling interest in subsidiaries     8,471
Total mezzanine equity 102,322 109,550
Stockholders’ equity:
Common stock 11,436 11,426
Paid-in capital 391,039 364,908
Common stock in treasury, at cost (9,863 ) (8,277 )
Accumulated other comprehensive loss (25,867 ) (21,247 )
Retained earnings (deficit)   17,582   (39,214 )
Total ADS stockholders’ equity 384,327 307,596
Noncontrolling interest in subsidiaries   13,986   16,663
Total stockholders’ equity   398,313   324,259
Total liabilities, mezzanine equity and stockholders’ equity $ 1,042,159 $ 1,043,242
 
 
ADVANCED DRAINAGE SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
 
  Fiscal Year Ended March 31,
(Amounts in thousands) 2019   2018
Cash Flow from Operating Activities
Net income $ 81,466 $ 64,792
Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation and amortization 71,900 75,003
Deferred income taxes 12,813 (11,239 )
Loss on disposal of assets and costs from exit and disposal
activities
3,647 12,655
ESOP and stock-based compensation 21,828 18,845
Amortization of deferred financing charges 735 934
Fair market value adjustments to derivatives 2,346 (3,244 )
Equity in net loss (income) of unconsolidated affiliates 95 739
Other operating activities (5,219 ) 1,010
Changes in working capital:
Receivables (17,953 ) (4,327 )
Inventories (2,034 ) (4,841 )
Prepaid expenses and other current assets (1,004 ) 1,648
Accounts payable, accrued expenses, and other liabilities   (16,942 )   (14,855 )
Net cash provided by operating activities 151,678 137,120
Cash Flows from Investing Activities
Capital expenditures (43,412 ) (41,709 )
Cash paid for acquisitions, net of cash acquired (1,990 )
Proceeds from sale of corporate-owned life insurance 13,644
Other investing activities   868   (390 )
Net cash used in investing activities (42,544 ) (30,445 )
Cash Flows from Financing Activities
Proceeds from Revolving Credit Facility 405,700 487,850
Payments on Revolving Credit Facility (442,800 ) (512,150 )
Payments on Term Loan (72,500 )
Proceeds from Senior Notes 75,000
Payments on Senior Notes (25,000 ) (25,000 )
Debt issuance costs (2,268 )
Equipment financing loans (909 )
Payments of notes, mortgages, and other debt (940 ) (1,905 )
Payments on capital lease obligations (24,284 ) (24,214 )
Acquisition of noncontrolling interest in BaySaver (8,800 )
Cash dividends paid (26,148 ) (18,478 )
Proceeds from exercise of stock options 5,908 9,087
Repurchase of common stock (7,947 )
Other financing activities   (382 )   (2,428 )
Net cash provided by financing activities (117,655 ) (94,953 )
Effect of exchange rate changes on cash   (175 )   (585 )
Net change in cash (8,696 ) 11,137
Cash at beginning of period   17,587   6,450
Cash at end of period $ 8,891 $ 17,587
 

Selected Financial Data

The following tables set forth net sales by reportable segment for each
of the periods indicated.

               
Three Months Ended Fiscal Year Ended

(Amounts in thousands
except percentages)

March 31, % March 31, %
2019   2018 Variance 2019  

2018

Variance
Domestic    
Pipe $ 180,780 $ 161,364 12.0 % $ 868,805 $ 844,875 2.8 %
Allied Products   70,405   64,815 8.6 %   355,326   329,557 7.8 %
Domestic net sales $ 251,185 $ 226,179 11.1 % $ 1,224,131 $ 1,174,432 4.2 %
International
Pipe $ 14,800 $ 17,647 (16.1 %) $ 122,836 $ 119,207 3.0 %
Allied Products   6,233   6,288 (0.9 %)   37,766   36,715 2.9 %
International net sales $ 21,033 $ 23,935 (12.1 %) $ 160,602 $ 155,922 3.0 %
Consolidated
Pipe $ 195,580 $ 179,011 9.3 % $ 991,641 $ 964,082 2.9 %
Allied Products   76,638   71,103 7.8 %   393,092   366,272 7.3 %
Net sales $ 272,218 $ 250,114 8.8 % $ 1,384,733 $ 1,330,354 4.1 %
 

Employee Stock Ownership Plan (“ESOP”)

The Company established an ESOP to enable employees to acquire stock
ownership in ADS in the form of redeemable convertible preferred shares
(“preferred shares”). All preferred shares will be converted to common
shares by plan maturity, which will be no later than March 2023. The
ESOP’s conversion of preferred shares into common shares will have a
meaningful impact on net income, net income per share and common shares
outstanding. The common shares outstanding will be greater after
conversion.

Net Income

The impact of the ESOP on net income includes the ESOP deferred
compensation attributable to the preferred shares allocated to employee
accounts during the period, which is a non-cash charge to our earnings
and not deductible for income tax purposes.

   
Three Months Ended Fiscal Year Ended
March 31, March 31,
(Amounts in thousands) 2019     2018 2019     2018
Net income attributable to ADS $ 1,010 $ (5,703 ) $ 77,772 $ 62,007
ESOP deferred compensation 4,183 3,778 15,296 11,724
 

Common shares outstanding

The conversion of the preferred shares will increase the number of
common shares outstanding. Preferred shares will convert to common
shares at plan maturity, or upon retirement, disability, death or vested
terminations over the life of the plan.

Three Months Ended     Fiscal Year Ended
March 31, March 31,
(Shares in thousands) 2019     2018 2019     2018
Weighted average common shares outstanding – Basic   57,325   56,302   57,025   55,696
Conversion of preferred shares 17,460 18,030 17,640 18,298
Unvested restricted shares 43 270 43 270

Non-GAAP Financial Measures

This press release contains financial information determined by methods
other than in accordance with accounting principles generally accepted
in the United States of America (“GAAP”). ADS management uses non-GAAP
measures in its analysis of the Company’s performance. Investors are
encouraged to review the reconciliation of non-GAAP financial measures
to the comparable GAAP results available in the accompanying tables.

Reconciliation of Non-GAAP Financial Measures

This press release includes references to Adjusted EBITDA and Free Cash
Flow, non-GAAP financial measures. These non-GAAP financial measures are
used in addition to and in conjunction with results presented in
accordance with GAAP. These measures are not intended to be substitutes
for those reported in accordance with GAAP. Adjusted EBITDA and Free
Cash Flow may be different from non-GAAP financial measures used by
other companies, even when similar terms are used to identify such
measures.

EBITDA and Adjusted EBITDA are non-GAAP financial measures that comprise
net income before interest, income taxes, depreciation and amortization,
stock-based compensation, non-cash charges and certain other expenses.
The Company’s definition of Adjusted EBITDA may differ from similar
measures used by other companies, even when similar terms are used to
identify such measures. Adjusted EBITDA is a key metric used by
management and the Company’s board of directors to assess financial
performance and evaluate the effectiveness of the Company’s business
strategies. Accordingly, management believes that Adjusted EBITDA
provides useful information to investors and others in understanding and
evaluating our operating results in the same manner as the Company’s
management and board of directors. In order to provide investors with a
meaningful reconciliation, the Company has provided below
reconciliations of Adjusted EBITDA to net income.

Free Cash Flow is a non-GAAP financial measure that comprises cash flow
from operating activities less capital expenditures. Free Cash Flow is a
measure used by management and the Company’s board of directors to
assess the Company’s ability to generate cash. Accordingly, management
believes that Free Cash Flow provides useful information to investors
and others in understanding and evaluating our ability to generate cash
flow from operations after capital expenditures. In order to provide
investors with a meaningful reconciliation, the Company has provided
below a reconciliation of cash flow from operating activities to Free
Cash Flow.

The following tables present a reconciliation of EBITDA and Adjusted
EBITDA to Net Income and Free Cash Flow to Cash Flow from Operating
Activities, the most comparable GAAP measures, for each of the periods
indicated.

Reconciliation of Adjusted EBITDA to Net Income

   
Three Months Ended Fiscal Year Ended
March 31, March 31,
(Amounts in thousands) 2019   2018 2019   2018
Net income $ 1,893 $ (4,856 ) $ 81,466 $ 64,792
Depreciation and amortization 18,988 19,210 71,900 75,003
Interest expense 4,590 2,642 18,618 15,262
Income tax expense (benefit)   1,081   (4,401 )   30,049   11,411
EBITDA 26,552 12,595 202,033 166,468
Derivative fair value adjustments (575 ) 292 634 (443 )
Foreign currency transaction (gains) losses 90 1,130 314 (1,748 )

Loss on disposal of assets and costs from exit and disposal
activities

2,075 4,535 3,647 15,003

Unconsolidated affiliates interest, tax, depreciation and
amortization

226 632 1,463 2,692
Contingent consideration remeasurement 9 6 (6 ) 39
Stock-based compensation expense 1,503 1,981 6,532 7,121
ESOP deferred stock-based compensation 4,183 3,778 15,296 11,724
Executive retirement (benefit) expense 50 491 (178 ) 1,473
Restatement-related (benefit) costs 14 837 (1,924 ) 4,227
Legal settlement 200 2,000
Transaction costs 295 213 699 1,362
Impairment of investment in unconsolidated affiliate 312 312
Strategic growth and operational improvement initiatives   2,440     3,450  
Adjusted EBITDA $ 36,862 $ 27,002 $ 231,960 $ 210,230
 

Contacts

Michael Higgins
VP, Corporate Strategy & Investor Relations
(614)
658-0050
[email protected]

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Medical Cannabis Market Report 2024-2030: Asia-Pacific Set to Witness Robust Growth, Driven by R&D Discovery Initiatives

Published

on

Continue Reading

Cannabis

Rubicon Organics Reports Q1 2024 Financial Results

Published

on

Continue Reading

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

December 31, 

2024

2023

 

ASSETS

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Investments

2,000,000

2,000,000

Investments Held for Sale

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

$

346,606,776

$

358,144,332

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Total Liabilities

$

242,726,589

$

238,852,444

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Operating Revenues

Retail

$

37,633,252

$

35,820,111

Wholesale

3,898,320

4,058,925

Other

69,421

121,900

Total Revenue

41,600,993

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Loss on Investment

(33,382)

Unrealized Gain on Investment

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

4,662,178

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

1,004,345

(637,225)

Loss on Investment

202,111

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Interest Expense, net

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

35,068

Severance

484,561

118,436

Retention Program Expenses

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania